Back to 
Davenport & Co LLC
Davenport & Co LLC
TGTX
Showing 0 of 9 quarters
Position history for Davenport & Co LLC's holdings in TG Therapeutics, Inc.
No. Davenport exited its TGTX (TG Therapeutics) position in Q4 2022. Its Q3 2022 13F listed 12,200 shares worth $72,000. Davenport first reported TGTX in Q2 2020 and held it in 7 quarterly 13F filings.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.